Goldman's Haider: Pivotal Year for Obesity Market in Pharma
Market Intelligence Analysis
AI-PoweredGoldman Sachs predicts 2026 to be a pivotal year for the obesity market due to upcoming oral drug launches, with investor psychology closely tied to their performance.
Market impact analysis based on bullish sentiment with 80% confidence.
Article Context
Asad Haider, head of the U.S. Healthcare Business Unit at Goldman Sachs Research, says 2026 is a pivotal year for the obesity market due to upcoming oral drug launches. He tells Romaine Bostick and Katie Greifeld on “The Close” that investor psychology around the sector this year will be closely tied to how those launches perform. (Source: Bloomberg)
Analysis and insights provided by AnalystMarkets AI.